Pro-Dex (PDEX) Peer Comparison

$64.86

$1.02 (1.60%)

As on 27-Aug-2026 16:00EDT

Market cap

$210 Mln

Revenue (TTM)

$75 Mln

P/E Ratio

18.4

P/B Ratio

4.7

Div. Yield

0 %

Edit

	Pro-Dex (PDEX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Market cap ($ Mln)	210	12,753	10,906	9,762	10,222
Revenue ($ Mln)	75	1,505	613	2,589	785
Net Profit ($ Mln)	12.00	160.59	-188.05	222.40	41.54
Net Margin (%)	16.08	10.67	-30.68	8.59	5.29
RoE (%)	27.68	10.86	-28.10	3.04	1.97
Price to Earnings	18.40	79.35	--	44.47	251.57
Price-To-Book	4.73	8.41	16.38	1.26	4.84

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Pro-Dex (PDEX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Operating Revenue	74.64	1,504.87	612.84	2,589.30	785.10
Cost of Revenue	53.90	483.98	127.96	1,245.50	384.30
Gross Profit	19.51	942.44	393.22	1,343.60	347.62
Operating Expenses	9.93	833.56	565.37	1,108.90	335.50
Operating Profit (EBIT)	10.81	187.34	-80.49	235.00	65.30
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	16.09	203.83	-192.83	350.40	52.15
Provision for Tax	4.09	43.24	-4.79	128.00	10.61
Profit after Tax (Net Income)	12.00	160.59	-188.05	222.40	41.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Pro-Dex (PDEX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Shareholder's Funds	45.20	1,530.77	682.49	7,173.90	2,112.03
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	15.14	210.18	135.71	2,116.80	705.49
Current Liabilities	14.64	233.78	102.33	961.30	132.66
Total Liabilities	61.19	1,826.52	893.49	10,576.50	2,949.70

Assets ($ Mln)

	Pro-Dex (PDEX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Non-Current Assets	21.27	630.60	404.74	7,231.50	1,749.63
Current Assets	53.71	1,344.12	515.78	3,020.50	1,200.55
Total Assets	61.19	1,826.52	893.49	10,576.50	2,949.70
Total Debt*	20.17	212.71	102.84	1,203.70	690.94
Net Current Assets	39.07	1,110.35	413.45	2,059.20	1,067.90

Cashflow ($ Mln)

	Pro-Dex (PDEX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Cash From Operating Activities	-1.68	238.66	-46.34	532.20	117.42
Cash Flow from Investing Activities	-0.24	-404.59	-77.61	-189.70	-298.47
Cash from Financing Activities	-0.29	26.53	11.89	-283.20	-15.21
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Pro-Dex (PDEX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
ROCE (%)	18.39	11.76	-22.53	8.98	1.79
ROE (%)	27.68	10.86	-28.10	3.04	1.97
ROA (%)	13.94	7.95	-18.00	2.02	1.36
EBIT Margin (%)	23.25	13.63	-30.58	-5.99	9.87
Net Margin (%)	16.08	10.67	-30.68	8.59	5.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Pro-Dex (PDEX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Revenue Growth (%)	16.39	17.55	41.55	1.37	16.49
EBIT Growth (%)	37.18	17.49	-116.42	-131.06	920.91
Net Profit Growth (%)	28.11	8.72	-102.66	-30.32	400.42
EPS Growth (%)	29.53	8.12	-96.88	-29.66	394.30
Book Value Growth (%)	30.75	17.33	-12.65	2.19	2.16

Valuation Ratios

	Pro-Dex (PDEX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Price / Earnings	16.29	68.93	-34.59	--	189.42
Price / Book Value	3.99	8.58	9.90	--	4.40
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	11.02	53.25	-43.50	--	55.90
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Pro-Dex (PDEX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debt to Equity	0.32	0.00	0.00	0.11	0.26
Short term debt to equity ratio	0.11	0.01	0.00	0.06	0.01
Current Ratio	3.67	5.75	5.04	3.14	9.05
Quick Ratio	2.14	3.86	4.46	2.33	7.64
Interest Coverage	21.92	157.91	-38.31	8.18	3.36

Operating Efficiency Ratios

	Pro-Dex (PDEX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debtors to sales (%)	26.49	12.65	22.67	17.06	20.09
Asset Turnover	0.87	0.74	0.59	0.24	0.26
Receivable days	86.05	46.54	60.95	65.39	72.41
Inventory Days	145.38	331.92	193.84	221.09	146.53
Payable days	35.40	26.16	60.19	37.02	29.05
Cash Conversion Cycle	196.03	352.30	194.60	249.46	189.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly